Truist analyst Joon Lee raised the firm’s price target on Viking Therapeutics to $32 from $28 and keeps a Buy rating on the shares. The company’s VK2735 data positions VK2735 as potentially best-in-class drug for weight loss, even ahead of tirzepatide, the analyst tells investors in a research note. Taking a playbook from semaglutide, Viking is also developing an oral formulation of VK2735, currently in Phase 1 study, with data expected in the second half of the year, Truist added.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VKTX:
- Viking Therapeutics price target raised to $19 from $15 at Roth MKM
- Viking Therapeutics price target raised to $25 from $15 at Maxim
- Viking Therapeutics price target raised to $35 from $12 at Raymond James
- Viking Therapeutics price target raised to $30 from $20 at Oppenheimer
- Stifel reiterates Buy on Viking Therapeutics, raises price target to $25